In 2021, 159 vaccine companies reach KRW 3,417.8 billion in domestic sales and KRW 628.7 billion in exports
– The Ministry of Health and Welfare and the Ministry of Industry jointly announced the results of the first vaccine industry survey –
– Host「Vaccine Industry Innovation Forum (12.6)」 to share important support projects with industry –
□ The Ministry of Health and Welfare (Minister Cho Kyu-hong) and the Ministry of Commerce, Industry and Energy (Minister Lee Chang-yang) jointly announced the results of the “National Vaccine Industry Survey of 2021,” including domestic sales, exports, announced the employment and investment status of vaccine industry on December 6 (Tuesday).
○ This survey was conducted by Korea Pharmaceutical Bio Association, Korea Fine Chemical Industry Promotion Association and Korea Evaluation Data, an institution specializing in credit investigation evaluation, and is significant as it was the first to conduct a specialized survey in the vaccine industry.
□ For this fact-finding, experts from various fields, such as bio, IT, chemistry, and machinery, prepared a classification system of vaccine industry* through several discussions, and finally selected 159 companies through total enumeration method, and conducted a research investigation. (Annex 2)
* The vaccine industry is divided into 4 areas: ❶ finished vaccine products, ❷ vaccine raw materials, ❸ vaccine equipment, and ❹ vaccine related services (consignment manufacturing, consignment development, consignment clinical trials, storage and transportation, etc.)
○ As a result of the fact-finding survey, it emerged that 159 national vaccine companies operate at a rate of 29.6% for finished vaccine products, 32.1% for vaccine raw materials, 15.1% for equipment for vaccines and 35.8% for vaccine-related services.
* Some vaccine companies are conducting two or more overlapping projects in four business areas
□ The detailed results for each sector of the national vaccine industry survey are as follows.
(Headquarters) Companies operating in the vaccine industry were located in Seoul (53 companies, 33.3%) and Gyeonggi (51 companies, 32.1%) according to their headquarters.
(Scale) Firm size is 3.1% (5) of large firms, 26.4% (42) of medium-sized firms, and 70.4% (112) of small and medium-sized firms.
* Manufacturing: 601 large enterprises (0.1%), 1,948 medium enterprises (0.4%), 548,095 small and medium enterprises (99.5%) (Source: National Statistical Office, Business statistics 2020)
– In terms of established capital, domestic companies (pure domestic capital) 90% (143), foreign companies (foreign capital) 5% (8), and joint ventures (foreign + domestic capital) 5% (8).
(Domestic Sales) The total domestic sales of the vaccine industry was noted at KRW 3,417.8 billion.
– By industry, 2.6865 trillion won for finished vaccine products, 86.5 billion won for vaccine raw materials, 69.4 billion won for vaccine equipment, and 636.1 billion won for vaccine related services.
(Export) The total amount of exports in the vaccine industry was 628.7 billion won.
– By sector, 563.7 billion won of finished vaccine products, 141 billion won of vaccine raw materials, 43 billion won of vaccine equipment, and 76.3 billion won of vaccine-related services were examined.
(Investments) Investments in the vaccine industry amount to KRW 331.4 billion, including KRW 214 billion for research and development and KRW 117.4 billion for investment in facilities.
– Considering the currently ongoing or future planned facility investment plans of more than 13 trillion won (July 27, 2022, Bio-Healthcare Industry Innovation Plan) by vaccine and bio companies, annual investment is expected in structures gradually expand.
* For reference, the total investment in vaccine companies is KRW 2,204.9 billion, of which 15.0% is for vaccines.
(Labour) Among vaccine companies, it was investigated that there are more than 10,758 people working in vaccine-related departments.
– By job position, production workers 4,715 (43.8%), research workers 2,772 (25.8%) and sales/․ There were 3,271 (30.4%) other positions such as management.
* For reference, the total workforce of 159 vaccine companies is 44,312.
□ The difficulties vaccine manufacturers encounter in the field are as follows.
* Some vaccine companies have written more than two duplicates due to business difficulties
(R&D) Regarding R&D, the difficulties were found in the order of lack of funds (47.2%, 75 companies), lack of professional manpower (25.2%, 40 companies), and lack of infrastructure such as research equipment (22.0%, 35 companies). .
(Commercialisation) Difficulties were encountered in the commercialization process in the order of lack of funds (40.3%, 64 companies), lack of relevant information such as market trends (24.5%, 39 companies), and lack of manpower professional (20.8%, 33 companies).
(Regulations) Regarding regulations, Ministry of Food and Pharmaceutical Safety approval/authorization (62.3%, 99 companies), clinical trials (37.1%, 59 companies), national release approval (28.3% , 45 companies) and National Immunization Supply System by the Agency for Disease Control and Prevention (25.2%, 40 companies) were in difficulty in the order.
□ The government comprehensively considers the connectivity, coherence and population design with the existing bioindustry survey conducted annually by the Ministry of Commerce, Industry and Energy, and review the national vaccine industry fact-finding survey to be approved as a national statistic from next year through consultation with the National Statistical Office
□ Meanwhile, the Ministry of Health and Welfare and the Ministry of Trade, Industry and Energy co-hosted the Joint Public-Private Vaccine Industry Innovation Forum to present key support projects of which vaccine companies are curious and to share recent national and international industry trends and statistical data.
* A detailed report on the results of the 2021 Vaccine Industry Survey will be published on the websites of Korea Health Industry Development Institute, Korea Pharmaceutical Bio Association and Korea Bio Association starting December 6 (Tuesday).
○ In this event, the tax credit support for private R&D and investment in the vaccine/bio industry, the support of the K-Bio/Vaccine Fund, the support for the construction of smart factories, were introduced, activities to support low-interest loans and activities to support expansion abroad. (Attachment 1)
□ Government ▸Increase the scale of the company so that the vaccine industry can develop into a strong backbone industry that will lead the biologic industry in the future, ▸Provide timely government support tailored to the growth cycle, ▸Develop and vaccine production, it is a policy to provide customized support for each ministry without interruption also for export.
○ In addition, there are various authorization and licensing regulations that vaccine companies experience in industry to seek solutions step by step and in sequence, focus on Global Vaccine Hub Promotion Team Business Difficulty Resolution Support Center together with Ministries related.
<붙임> 1. Overview of the Joint Public-Private Vaccine Industry Innovation Forum
2. Vaccine industry classification system